Xxrohxxlthxxlc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xxrohxxlthxxlc Pharmaceutical Import Records from India — 4 Products, $993.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxrohxxlthxxlc — Pharmaceutical Importer Profile (2026) | 4 Products, $993.5K Trade | TransData Nexus

Xxrohxxlthxxlc

Pharmaceutical Importer · United States · Respiratory & OTC Focus · $993.5K Total Trade · DGFT Verified

Xxrohxxlthxxlc is a pharmaceutical importer based in United States with a total trade value of $993.5K across 4 products in 3 therapeutic categories. Based on 20 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxrohxxlthxxlc sources from 2 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 75.6% of imports.

Xxrohxxlthxxlc — Import Portfolio & Supplier Network

Xxrohxxlthxxlc import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxrohxxlthxxlc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$1.6M	37	75.6%
Apl Healthcare Limited	$509.4K	21	24.4%

Xxrohxxlthxxlc sources from 2 verified Indian suppliers across .

What Formulations Does Xxrohxxlthxxlc Import?

Formulation	Value	Ships
Acetaminophen tablets 650 MG 325's	$302.7K	7
Omeprazole magnesium delayed-release TAB	$193.4K	4
Guaifenesin & dextromethorphan hbr	$172.6K	4
Esomeprazole capsules 20 MG 42's	$150.0K	3
Famotidine tablets 20 MG 200's	$150.0K	3
Loperamide hydrochloride tablets 2 MG	$132.4K	4
Acetaminophen gelcaps 500MG	$116.9K	4
Acetaminophen chewable tablets 160 MG	$105.5K	6
Famotidine tablets 20 MG 90's	$100.0K	2
Naproxen sodium tablets 220 MG 24's	$100.0K	2
Diclofenac sodium topical gel 1	$70.3K	4
Esomeprazole capsules 20 MG 14's	$50.0K	1
Nicotine polacrilex lozenge 4 MG	$50.0K	1
Nicotine polacrilex lozenge 2 MG	$50.0K	1
Esomeprazole capsules 20 MG 50000's	$50.0K	1

Xxrohxxlthxxlc imports 24 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Famotidine	Gastrointestinal	$400.0K	8	0.7%	5
2	Guaifenesin	Respiratory & OTC	$293.5K	6	1.1%	15
3	Dextromethorphan	Respiratory & OTC	$200.0K	4	1.3%	14
4	Nicotine	Other	$100.0K	2	0.7%	2

Xxrohxxlthxxlc imports 4 pharmaceutical products across 3 categories into United States totaling $993.5K.

Xxrohxxlthxxlc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxrohxxlthxxlc is a United States-based pharmaceutical importer specializing in the procurement of finished pharmaceutical formulations from India. Operating as a buyer, the company plays a pivotal role in the U.S. pharmaceutical distribution network by sourcing a diverse range of medications to meet domestic demand. While specific details about its headquarters and parent company are not publicly disclosed, Xxrohxxlthxxlc's operations are integral to the supply chain, ensuring the availability of essential pharmaceutical products across the United States.

2Distribution Network

Xxrohxxlthxxlc's distribution network encompasses multiple warehouse locations strategically positioned to facilitate efficient logistics and timely delivery of pharmaceutical products throughout the United States. The company's logistics capabilities are designed to support nationwide coverage, ensuring that medications reach various regions promptly. While specific details about international distribution are not publicly available, Xxrohxxlthxxlc's focus remains on serving the U.S. market, leveraging its domestic infrastructure to maintain a robust supply chain.

3Industry Role

In the U.S. pharmaceutical supply chain, Xxrohxxlthxxlc functions primarily as a pharmaceutical importer and buyer. By sourcing finished pharmaceutical formulations from India, the company acts as an intermediary between Indian manufacturers and the U.S. market, facilitating the importation and distribution of these products. This role is crucial in ensuring the availability of a wide array of medications, including generics and over-the-counter drugs, thereby contributing to the overall accessibility and affordability of pharmaceuticals in the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxrohxxlthxxlc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxrohxxlthxxlc's sourcing strategy exhibits a high degree of concentration, with 75.6% of its total import value from India attributed to AUROBINDO PHARMA LIMITED and 24.4% to APL HEALTHCARE LIMITED. This significant reliance on two suppliers suggests a strategic choice aimed at streamlining procurement processes and potentially negotiating better terms. However, such concentration also introduces risks related to supply chain disruptions, quality control issues, and regulatory compliance challenges. The company's shipment data, comprising 37 shipments from AUROBINDO PHARMA LIMITED and 21 from APL HEALTHCARE LIMITED, indicates a stable relationship with these suppliers, as evidenced by the consistent volume of imports over the period. Nonetheless, the lack of diversification in sourcing could pose challenges in mitigating risks associated with supplier-specific issues.

2Supply Chain Resilience

Xxrohxxlthxxlc's supply chain resilience is closely tied to the stability and reliability of its primary Indian suppliers, AUROBINDO PHARMA LIMITED and APL HEALTHCARE LIMITED. The company's import portfolio includes 24 unique formulations, indicating a degree of diversification in product offerings. However, the heavy reliance on two suppliers may limit the company's ability to quickly adapt to supply chain disruptions or shifts in market demand. The exposure to shipping routes between India and the United States introduces potential vulnerabilities, including geopolitical risks, natural disasters, and logistical challenges. Ensuring that key suppliers adhere to Good Manufacturing Practice (GMP) standards is essential for maintaining product quality and regulatory compliance. While AUROBINDO PHARMA LIMITED and APL HEALTHCARE LIMITED are recognized entities in the pharmaceutical industry, Xxrohxxlthxxlc's supply chain resilience would benefit from a more diversified supplier base and comprehensive risk management strategies.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FDCA), which establishes the legal framework for drug approval, manufacturing, labeling, and distribution. For imported drugs, the FDA requires that they meet the same standards for quality, safety, and effectiveness as domestically produced drugs. This includes compliance with Good Manufacturing Practice (GMP) regulations, proper labeling, and approval for marketing in the U.S. market. The FDA's role is critical in ensuring that imported pharmaceutical products, including those from India, adhere to these stringent standards to protect public health.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Importers must ensure that their products are approved by the FDA and comply with all applicable regulations. This includes obtaining necessary import permits and ensuring that products are manufactured in facilities that adhere to GMP standards recognized by the FDA. GMP certification from reputable organizations, such as the European Medicines Agency (EMA) or the World Health Organization (WHO), is often recognized by the FDA, provided that the manufacturing processes meet the FDA's standards. Importers must also ensure that they have the appropriate wholesale distribution authorization to handle and distribute pharmaceutical products within the United States.

Xxrohxxlthxxlc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxrohxxlthxxlc's product strategy focuses on importing finished pharmaceutical formulations across three therapeutic categories: Respiratory & OTC (49.7%), Gastrointestinal (40.3%), and Other (10.1%). The top five products imported include Famotidine, Guaifenesin, Dextromethorphan, and Nicotine, with Famotidine being the highest in value at $400K. This strategic focus aligns with market demand for treatments in these therapeutic areas, addressing prevalent health conditions and consumer needs. The emphasis on Respiratory & OTC and Gastrointestinal products suggests a targeted approach to meet the significant demand for over-the-counter and prescription medications in these categories.

2Sourcing Profile

Xxrohxxlthxxlc's sourcing strategy is centered on importing generic drug formulations from India, leveraging the country's established pharmaceutical manufacturing capabilities. The company's portfolio includes a diverse range of formulations, indicating a preference for products that offer therapeutic efficacy and market competitiveness. India's role as a major supplier of generic pharmaceuticals positions it as a key partner in Xxrohxxlthxxlc's procurement strategy, enabling the company to offer a broad spectrum of medications to the U.S. market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Xxrohxxlthxxlc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Xxrohxxlthxxlc, particularly those offering products that complement the company's existing portfolio or address unmet market needs. The company's concentrated sourcing strategy suggests that introducing alternative suppliers could help mitigate risks associated with supplier dependency and enhance supply chain resilience. Identifying gaps in Xxrohxxlthxxlc's current sourcing, such as specific formulations or therapeutic areas not currently covered, presents an opportunity for Indian exporters to establish partnerships and expand their market presence in the U.S.

2Requirements & Qualifications

Indian exporters seeking to supply Xxrohxxlthxxlc and the U.S. market must ensure that their products comply with FDA regulations, including obtaining necessary import permits and adhering to GMP standards recognized by the FDA. Products must undergo batch testing to verify quality and stability,

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Xxrohxxlthxxlc

What products does Xxrohxxlthxxlc import from India?

Xxrohxxlthxxlc imports 4 pharmaceutical products across 3 categories. Top imports: Famotidine ($400.0K), Guaifenesin ($293.5K), Dextromethorphan ($200.0K), Nicotine ($100.0K).

Who supplies pharmaceuticals to Xxrohxxlthxxlc from India?

Xxrohxxlthxxlc sources from 2 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (75.6% of imports, $1.6M).

What is Xxrohxxlthxxlc's total pharmaceutical import value?

Xxrohxxlthxxlc's total pharmaceutical import value from India is $993.5K, based on 20 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxrohxxlthxxlc focus on?

Xxrohxxlthxxlc imports across 3 categories. The largest: Respiratory & OTC (49.7%), Gastrointestinal (40.3%), Other (10.1%).

Get Full Xxrohxxlthxxlc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.